Coronavirus treatment: 5 Indian firms in licensing pact with Merck for Covid-19 oral drug
- Molnupiravir is an investigational oral antiviral agent, currently being studied in a Phase 3 trial for the treatment of non-hospitalised patients with confirmed COVID-19
- Meanwhile, Natco Pharma has already applied to India's CDSCO to conduct Phase 3 trials of Molnupiravir